Traditional Chinese medicine differentiation and treatment of type Ⅱ cardiorenal syndrome based on the theory of “heart vessel-Xuanfu-kidney collateral”
LIU Jiayou,ZHAO Yun,WANG Manrui,et al.Traditional Chinese medicine differentiation and treatment of type Ⅱ cardiorenal syndrome based on the theory of “heart vessel-Xuanfu-kidney collateral”[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(09):1049-1053.
LIU Jiayou,ZHAO Yun,WANG Manrui,et al.Traditional Chinese medicine differentiation and treatment of type Ⅱ cardiorenal syndrome based on the theory of “heart vessel-Xuanfu-kidney collateral”[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(09):1049-1053. DOI: 10.16025/j.1674-1307.2024.09.018.
RANGASWAMI J, BHALLA V, BLAIR JEA, et al. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association[J]. Circulation, 2019,139(16):e840-e878.
DAMMAN K, VALENTE MA, VOORS AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis[J]. Eur Heart J, 2014,35(7):455-469.
XU X, ZHANG B, WANG Y, et al. Renal fibrosis in type 2 cardiorenal syndrome: An update on mechanisms and therapeutic opportunities[J]. Biomed Pharmacother, 2023,164:114901.
ZHAO Y, WANG C, HONG X, et al. Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome[J].Kidney Int,2019,95(4):815-829.
QIU Q, CAO J, WANG Y, et al. Time course of the effects of buxin yishen decoction in promoting heart function and inhibiting the progression of renal fibrosis in myocardial infarction caused type 2 cardiorenal syndrome rats[J]. Front Pharmacol, 2019,10:1267.
ZANNAD F, ROSSIGNOL P. Cardiorenal syndrome revisited[J]. Circulation, 2018,138(9):929-944.
JENTZER JC, BIHORAC A, BRUSCA SB, et al. Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome: JACC council perspectives[J].J Am Coll Cardiol,2020,76(9):1084-1101.